Emergence and outcomes of the SARS-CoV-2 ‘Marseille-4’ variant
Background: In Marseille, France, following a first severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak in March–May 2020, a second epidemic phase occurred from June, involving 10 new variants. The Marseille-4 variant caused an epidemic that started in August and is still ongoing. Methods: The 1038 SARS-CoV-2 whole genome sequences obtained in our laboratory by next-generation sequencing with Illumina technology were analysed using Nextclade and nextstrain/ncov pipelines and IQ-TREE. A Marseille-4-specific qPCR assay was implemented. Demographic and clinical features were compared between patients with the Marseille-4 variant and those with earlier strains. Results: Marseille-4 harbours 13 hallmark mutations. One leads to an S477N substitution in the receptor binding domain of the spike protein targeted by current vaccines. Using a specific qPCR, it was observed that Marseille-4 caused 12–100% of SARS-CoV-2 infections in Marseille from September 2020, being involved in 2106 diagnoses. This variant was more frequently associated with hypoxemia than were clade 20A strains before May 2020. It caused a re-infection in 11 patients diagnosed with different SARS-CoV-2 strains before June 2020, suggesting either short-term protective immunity or a lack of cross-immunity. Conclusions: Marseille-4 should be considered as a major SARS-CoV-2 variant. Its sudden appearance points towards an animal reservoir, possibly mink. The protective role of past exposure and current vaccines against this variant should be evaluated..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:106 |
|---|---|
| Enthalten in: |
International Journal of Infectious Diseases - 106(2021), Seite 228-236 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pierre-Edouard Fournier [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
COVID-19 |
|---|
| doi: |
10.1016/j.ijid.2021.03.068 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ001326155 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ001326155 | ||
| 003 | DE-627 | ||
| 005 | 20230309162445.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2021.03.068 |2 doi | |
| 035 | |a (DE-627)DOAJ001326155 | ||
| 035 | |a (DE-599)DOAJf21d38f3597a4ff5bf45e0938d586b49 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC109-216 | |
| 100 | 0 | |a Pierre-Edouard Fournier |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Emergence and outcomes of the SARS-CoV-2 ‘Marseille-4’ variant |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background: In Marseille, France, following a first severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak in March–May 2020, a second epidemic phase occurred from June, involving 10 new variants. The Marseille-4 variant caused an epidemic that started in August and is still ongoing. Methods: The 1038 SARS-CoV-2 whole genome sequences obtained in our laboratory by next-generation sequencing with Illumina technology were analysed using Nextclade and nextstrain/ncov pipelines and IQ-TREE. A Marseille-4-specific qPCR assay was implemented. Demographic and clinical features were compared between patients with the Marseille-4 variant and those with earlier strains. Results: Marseille-4 harbours 13 hallmark mutations. One leads to an S477N substitution in the receptor binding domain of the spike protein targeted by current vaccines. Using a specific qPCR, it was observed that Marseille-4 caused 12–100% of SARS-CoV-2 infections in Marseille from September 2020, being involved in 2106 diagnoses. This variant was more frequently associated with hypoxemia than were clade 20A strains before May 2020. It caused a re-infection in 11 patients diagnosed with different SARS-CoV-2 strains before June 2020, suggesting either short-term protective immunity or a lack of cross-immunity. Conclusions: Marseille-4 should be considered as a major SARS-CoV-2 variant. Its sudden appearance points towards an animal reservoir, possibly mink. The protective role of past exposure and current vaccines against this variant should be evaluated. | ||
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Variant | |
| 650 | 4 | |a Marseille-4 | |
| 650 | 4 | |a Mutations | |
| 650 | 4 | |a Spike | |
| 653 | 0 | |a Infectious and parasitic diseases | |
| 700 | 0 | |a Philippe Colson |e verfasserin |4 aut | |
| 700 | 0 | |a Anthony Levasseur |e verfasserin |4 aut | |
| 700 | 0 | |a Christian A. Devaux |e verfasserin |4 aut | |
| 700 | 0 | |a Philippe Gautret |e verfasserin |4 aut | |
| 700 | 0 | |a Marielle Bedotto |e verfasserin |4 aut | |
| 700 | 0 | |a Jeremy Delerce |e verfasserin |4 aut | |
| 700 | 0 | |a Ludivine Brechard |e verfasserin |4 aut | |
| 700 | 0 | |a Lucile Pinault |e verfasserin |4 aut | |
| 700 | 0 | |a Jean-Christophe Lagier |e verfasserin |4 aut | |
| 700 | 0 | |a Florence Fenollar |e verfasserin |4 aut | |
| 700 | 0 | |a Didier Raoult |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t International Journal of Infectious Diseases |d Elsevier, 2015 |g 106(2021), Seite 228-236 |w (DE-627)DOAJ000043923 |x 18783511 |7 nnns |
| 773 | 1 | 8 | |g volume:106 |g year:2021 |g pages:228-236 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ijid.2021.03.068 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/f21d38f3597a4ff5bf45e0938d586b49 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1201971221002861 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1201-9712 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 106 |j 2021 |h 228-236 | ||